Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report)'s share price shot up 8.7% during mid-day trading on Friday . The stock traded as high as $8.38 and last traded at $8.24. 3,353,225 shares changed hands during mid-day trading, an increase of 22% from the average session volume of 2,739,171 shares. The stock had previously closed at $7.58.
Analyst Ratings Changes
A number of equities analysts have issued reports on NTLA shares. Guggenheim reduced their target price on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Chardan Capital restated a "buy" rating and set a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. Canaccord Genuity Group dropped their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research note on Tuesday. Finally, Wolfe Research raised Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective for the company in a research report on Monday, April 21st. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $34.95.
Check Out Our Latest Stock Report on Intellia Therapeutics
Intellia Therapeutics Stock Up 10.1%
The company has a market cap of $864.40 million, a P/E ratio of -1.53 and a beta of 2.33. The company's 50-day moving average is $7.90 and its two-hundred day moving average is $10.10.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. During the same period in the prior year, the company earned ($1.12) EPS. The firm's quarterly revenue was down 42.6% on a year-over-year basis. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.
Institutional Trading of Intellia Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 3.8% in the first quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company's stock worth $92,508,000 after purchasing an additional 474,629 shares during the period. Vanguard Group Inc. grew its holdings in shares of Intellia Therapeutics by 5.5% during the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after purchasing an additional 561,978 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in Intellia Therapeutics in the fourth quarter valued at approximately $43,177,000. Geode Capital Management LLC grew its stake in Intellia Therapeutics by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after buying an additional 45,930 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock worth $23,300,000 after buying an additional 970,700 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
